ASTERAND Accredited Human Cancer Tissue

SUBTYPE:AccreditedCentral Nervous SystemEndocrineGastrointestinalHair/Skin/NailsHead and NeckLiverMammaryReproductiveRespiratoryUrinary
DISEASE FOCUS:Endocrinology/ MetabolismOncology
DISEASE SUBCATEGORIES:Bladder CancerBrain CancerBreast CancerCervical CancerColorectal CancerEsophageal CancerHead and Neck CancerKidney CancerLiver CancerLung CancerOther CancerOvarian CancerPancreatic CancerProstate CancerSkin CancerStomach CancerThyroid CancerUterine Cancer
APPLICATION & SPECIALITY USES:Biomarker DiscoveryImmuno-oncologyPersonalized Medicine
Keywords:AccreditedASTERANDCancer TissueCarcinomaHuman Tissue

BioIVT is proud to announce our ASTERAND® Accredited Human Tissue Products. A new solution for those requiring quality, board certified pathology confirmed diagnosis but with limited data requirements. Available for most Solid Tumor indications.

  • Low-data set including gender, age, race, year of excision and organ of excision
  • Same ASTERAND Board-certified Pathology Review for confirmed tissue diagnosis
  • Same ASTERAND Human Tissue Quality with links to Aperio full slide image
  • Same ASTERAND ethical collections with links to regulatory documentation included
  • Percent tumor guaranteed to be between 25-100%
  • Low user failure rating – consistently less than 1% for over 20 years and for over 1,000,000 processed samples


ASTERAND Accredited

Human Tissue


Human Tissue

Board-Certified Pathology Review to confirm specimen diagnosis

Confirmed specimen diagnosis

Confirmed specimen diagnosis with tumor grade

Link to high-resolution, whole slide images of specimens using Leica Biosystems’ Aperio System

Ethically procured – Links to regulatory documentation included

Associated Socio-demographic Data Set

Donor Age, Gender, Race

Donor Age, Gender, Race, Ethnicity, Smoking history, Alcohol history, Female reproductive history, and more

Associated Clinical Data Set

Resection organ, year of resection

Comprehensive, >300 data points inclusive of clinical donor diagnosis, comorbidities, treatments (current and past), medications

Associated Specimen Data Set

Percent tumor between 25-100% guaranteed

Comprehensive, including percent tumor, necrosis, normal and other; ischemic time, specimen size/weight

Associated Outcomes Data


Available for some cohorts, inquire for more information

Lowest user failure rate



Tissue formats available


FFPE, Fresh Frozen w/ matched biofluids


This material should be handled as if capable of transmitting infectious agents. Please use universal precautions. No test method can provide total assurance that Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, or other infectious agents are absent.

This product is being sold for research and/or manufacturing purposes only. It is not to be used in humans or animals and further manufacturing that will result in a finished product that contains viable cells is prohibited. For in vitro use only. The user assumes all responsibility for its usage and disposal, in accordance with all regulations.

  • Standard process requires that tissues are excised and processed with less than 30 minutes cold ischemic time.
  • Fixed samples are placed in 10% neutral buffered formalin for a minimum of 4 hours to ensure thorough fixation but no longer than 72 hours.
  • One section (minimum) is removed from each tissue block and stained with H&E for quality review.
  • Tissue is evaluated by board certified pathologists to ensure tissue origin and diagnosis are consistent with clinical data.
  • Tissue quality and integrity is characterized for paraffin quality, tissue size and processing quality.
  • Sample Level Tumor (STMR) is determined for malignant samples.
  • Normal tissue cellular composition is evaluated to estimate percentage(%) of parenchyma present in the sample.
  • BioIVT upholds the fundamental bioethics principles of autonomy, privacy, safety and informed consent. We support legal and ethical efforts to promote voluntary donation of surplus human tissues and clinical information for research use. In general, the tissue BioIVT receives is surplus surgical tissue that would otherwise be discarded following surgery performed for medical treatment.  BioIVT maintains a global network of collaborators who conduct subject recruitment, informed consent and scientific activities. We ensure that all of our activities, and those of our collaborators, are conducted in accordance with applicable laws, regulations, and ordinances. BioIVT confirms that the following activities have been completed by our collaborators (as necessary): institutional and independent review board approval, privacy officer authorization, government licenses, or industry accreditations. We continually monitor our practices to conform to evolving external scientific, legal and ethical requirements.